First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis

BackgroundImmune checkpoint inhibitors (ICIs) plus chemotherapy were unlikely to be considered cost-effective compared with chemotherapy as the first-line treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) in China due to its high costs. However, the cost-effectiveness of th...

Full description

Bibliographic Details
Main Authors: Shuo Kang, Xinchen Wang, Yue Zhang, Boyuan Zhang, Fangjian Shang, Wei Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
chemotherapy
extensive-stage small-cell lung cancer
cost-effectiveness
first-line treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.740091/full

Similar Items

Similar Items